Sierra Summit Advisors LLC Buys 9,305 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sierra Summit Advisors LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 67.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 23,075 shares of the biopharmaceutical company's stock after acquiring an additional 9,305 shares during the period. Sierra Summit Advisors LLC's holdings in Gilead Sciences were worth $2,131,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. McAdam LLC increased its holdings in Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after buying an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC increased its stake in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares during the last quarter. Global Financial Private Client LLC grew its holdings in Gilead Sciences by 1,222.0% during the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock worth $561,000 after purchasing an additional 5,609 shares during the period. Finally, Exome Asset Management LLC bought a new stake in Gilead Sciences in the third quarter valued at approximately $4,192,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Bank of America increased their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. The Goldman Sachs Group upped their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Trading Down 3.7 %

NASDAQ:GILD traded down $3.88 during mid-day trading on Thursday, hitting $101.37. 6,599,872 shares of the company's stock were exchanged, compared to its average volume of 7,457,527. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a 50 day simple moving average of $108.17 and a 200-day simple moving average of $96.52. The firm has a market capitalization of $126.22 billion, a P/E ratio of 274.32, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.12%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.